FibroGen, Inc. (FGEN)
| Market Cap | 87.16M |
| Revenue (ttm) | 154.98M |
| Net Income (ttm) | -294.18M |
| Shares Out | 98.34M |
| EPS (ttm) | -3.07 |
| PE Ratio | n/a |
| Forward PE | 61.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 997,866 |
| Open | 0.910 |
| Previous Close | 0.909 |
| Day's Range | 0.850 - 0.948 |
| 52-Week Range | 0.333 - 25.690 |
| Beta | 0.53 |
| Analysts | Sell |
| Price Target | 10.00 (+1,028.29%) |
| Earnings Date | Feb 26, 2024 |
About FGEN
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical developm... [Read more]
Financial Performance
In 2022, FibroGen's revenue was $140.73 million, a decrease of -40.19% compared to the previous year's $235.31 million. Losses were -$293.65 million, 1.25% more than in 2021.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for FGEN stock is "Sell." The 12-month stock price forecast is $10.0, which is an increase of 1,028.29% from the latest price.
News
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FibroGen, Inc. (NASDAQ: FGEN) on behalf of l...
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence ≥ 56 days with roxadustat vs. placebo (36.1% vs 11.5...
FibroGen Reports Third Quarter 2023 Financial Results
SAN FRANCISCO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2023 and provided an update on the Company's recent developments.
FibroGen to Report Third Quarter 2023 Financial Results
SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also c...
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ...
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, In...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, In...
FibroGen shares fall after failure in late-stage study of Duchenne muscular dystrophy treatment
Shares of FibroGen Inc. FGEN, +3.23% fell 23% premarket on Wednesday after the company said its investigational treatment for Duchenne muscular dystrophy failed to meet its primary and secondary endpo...
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
– Study did not meet the primary endpoint – – Pamrevlumab was generally safe and well tolerated – SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced topline...
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ...
FibroGen Reports Second Quarter 2023 Financial Results
SAN FRANCISCO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2023 and provided an update on the Company's recent developments.
FibroGen Announces Leadership Transition
Appoints Thane Wettig as Interim Chief Executive Officer Wettig succeeds Enrique Conterno and brings over 30 years of global pharmaceutical leadership SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) -- ...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("...
FibroGen to Report Second Quarter 2023 Financial Results
SAN FRANCISCO, July 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2023 financial results on Monday, August 7 after the market close. FibroGen will also co...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("...
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("...
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This MonthSilk Road Me
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are advised to cont...
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("F...
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("F...
INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Fibrogen, Inc. and Encourages Investors With Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)---- $FGEN #FGEN--The Schall Law Firm Announces It Is Investigating Claims Against Fibrogen, Inc. and Encourages Investors With Losses to Contact the Firm.
FibroGen's lung disease treatment fails in late-stage trial
FibroGen said on Monday its experimental drug, pamrevlumab, for treating lung disease idiopathic pulmonary fibrosis (IPF) did not meet its main goal in a late-stage study.
FibroGen to discontinue late-stage trial of treatment for idiopathic pulmonary fibrosis, cut costs to extend cash runway to 2026
FibroGen Inc. FGEN, -4.06% said Monday it is discontinuing a late-stage trial of a treatment for idiopathic pulmonary fibrosis after it failed to meet its main goal. The San Francisco-based biotech sa...
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
- Study did not meet the primary endpoint - Pamrevlumab was generally safe and well tolerated - ZEPHYRUS-2 Phase 3 study will be discontinued - Company to implement plan to extend cash runway into...